FT011
Diabetic Kidney Disease
Key Facts
About Gyre Therapeutics
Gyre Therapeutics is advancing a pipeline of small molecule therapies designed to treat serious fibrotic and metabolic disorders with high unmet medical need. The company's lead program, FT011, represents a novel mechanism of action targeting fibrosis through selective inhibition of key pathways. With a valuation of approximately $640 million and a public listing, Gyre is positioned to advance its clinical programs through key data readouts. The company's approach focuses on diseases where fibrosis plays a central role in disease progression and organ dysfunction.
View full company profileAbout Gyre Therapeutics
Gyre Therapeutics is advancing a pipeline of small molecule therapies designed to treat serious fibrotic and metabolic disorders with high unmet medical need. The company's lead program, FT011, represents a novel mechanism of action targeting fibrosis through selective inhibition of key pathways. With a valuation of approximately $640 million and a public listing, Gyre is positioned to advance its clinical programs through key data readouts. The company's approach focuses on diseases where fibrosis plays a central role in disease progression and organ dysfunction.
View full company profileTherapeutic Areas
Other Diabetic Kidney Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| CB1 receptor blocker | Novo Nordisk | Phase 2 |
| Kerendia (finerenone) | Bayer | Approved |